LMWH – Page 6 – Communicable Diseases Research

The Role of Therapeutic Anticoagulation in COVID-19

Case Report

Published on 2020-08-272022-10-31
Journal: Case Reports in Critical Care [Category] COVID-19,

Beneficial non-anticoagulant mechanisms underlying heparin treatment of COVID-19 patients

Review

Published on 2020-08-252022-10-04
Journal: EBioMedicine [Category] MERS, SARS, 치료법,

[키워드] addition AKI, acute kidney injury Anticoagulant ARDS, acute respiratory distress syndrome chemokines clinical study COVID-19 COVID-19 patient COVID-19 patients COVID-19, coronavirus disease-2019 endothelial evaluate explained Extracellular functional GAGs, glycosaminoglycans Heparanase heparin Histones HPSE, heparanase HS, heparan sulphate ICU, Intensive care unit Inflammation Inflammatory Inflammatory diseases inhibition Interference IU, international unit kidney leukocyte LMWH LMWH, low molecular weight heparin low molecular weight heparin lung mechanism MERS-CoV, Middle East respiratory syndrome coronavirus molecular weight Mortality NETs, neutrophil extracellular traps pathogenic mechanism Patient report responsible SARS-CoV-2, Severe acute respiratory syndrome coronavirus 2 SARS-CoV, severe acute respiratory syndrome coronavirus sequence severe inflammation SGP, spike glycoprotein therapeutic dose therapeutic potential Treatment viral cellular entry
[DOI] 10.1016/j.ebiom.2020.102969 PMC 바로가기 [Article Type] Review

Multi-centre, three arm, randomized controlled trial on the use of methylprednisolone and unfractionated heparin in critically ill ventilated patients with pneumonia from SARS-CoV-2 infection: A structured summary of a study protocol for a randomised controlled trial

Letter

Published on 2020-08-172022-10-29
Journal: Trials [Category] Coronavirus, MERS,

[키워드] 24 hour absolute reduction Administered administration AIFA airway allocation sequence Alpha Anticoagulant anticoagulant therapy Anticoagulant treatment approval Arm Aspergillus assigned assumption average bleeding bleeding event blinded Block randomisation block size BMI Brain Breastfeeding Candida checked childbearing age chronic clinical clinical condition clinically combined use conjunctival contributed corpus Corticosteroid COVID-19 criteria Critical Critically ill cytomegalovirus D-dimer level death defined Delay detect diagnostic discharge dissemination dosage drug dysfunction effective element eligible patient enoxaparin enrolled EudraCT exclusion criteria expected hematemesis hematoma heparin-induced thrombocytopenia Herpe high risk High-dose history hospital hospital discharge Hypothesis ICU ICU free day ICU Patients impairing Inclusion inclusion criteria indicated Infection initial Inpatient intensive care unit interval Intervention Intra-articular intramuscular intravenously invasive Invasive mechanical ventilation investigator Italian limit LMWH low molecular weight low-molecular weight heparin macroscopic major bleeding mechanical ventilation medical intervention Methylprednisolone Mortality mortality rate Myocardial Non-invasive non-invasive ventilation number objective occur ophthalmic organ dysfunction PaO parallel group participant Patient performed Pharyngeal swab Pneumonia positive positive pressure pregnancy test Presence Prophylactic prophylactic dose Prophylaxis protocol random randomisation randomised randomised controlled trial randomization Randomized Randomized controlled trial Randomly Ratio receive recent recruited recruitment Rectal Bleeding red blood cell reduce reducing Registered required risk of death Safety Sample size SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 pneumonia secondary secure severe disease sick significantly sodium status steroid stratified stroke study drug Study protocol subcutaneously surgical syndrome therapeutic therapeutic doses therapy Treatment treatment group unfractionated heparin Venous Thromboembolism ventilated patient Ventilation website Weighting Withdrawal women
[DOI] 10.1186/s13063-020-04645-z PMC 바로가기 [Article Type] Letter

Preliminary Experience With Low Molecular Weight Heparin Strategy in COVID-19 Patients

Pharmacology

Published on 2020-08-062022-10-31
Journal: Frontiers in Pharmacology [Category] COVID-19,

[키워드] 95% CI administration Admission all-cause mortality analyzed anticoagulation association clinical collected Consensus COVID- 19 COVID-19 COVID-19 patient demographic characteristics disease dosage DVT DVT prophylaxis Efficacy Evidence experience group heparin hospitalized COVID-19 patients hospitalized patients hypertension In-hospital in-hospital mortality incidence intermediate Laboratory Laboratory testing laboratory-confirmed LMWH LMWH (low molecular weight heparin) low molecular weight Mortality Older age pathophysiological Patient patients Prevalence Prophylactic Prophylaxis regimen remained Result significant difference significantly Strategy subgroups therapy thrombosis treated Treatment variable weight
[DOI] 10.3389/fphar.2020.01124 PMC 바로가기 [Article Type] Pharmacology

Venous thromboembolism in critically ill COVID-19 patients receiving prophylactic or therapeutic anticoagulation: a systematic review and meta-analysis

Article

Published on 2020-08-032022-10-30
Journal: Journal of Thrombosis and Thrombolysis [Category] COVID-19, SARS,

[키워드] 95% CI 95% confidence interval Analysis Anticoagulant anticoagulation approach calculated Care China Coronavirus 2019 COVID-19 COVID-19 patient COVID-19 patients Critically ill database event Evidence hypercoagulable ICU patient intensive care intensive care unit intensive care units LMWH management Meta-analysis novel coronavirus disease pandemic Patient performed Prevalence Prevent Prophylactic prophylactic dose proportion random-effects model receiving reported searched supplementary material systematic review therapeutic therapeutic anticoagulation therapeutic doses Thromboembolism Thromboprophylaxis unfractionated heparin venous thromboembolic Venous Thromboembolism VTE
[DOI] 10.1007/s11239-020-02235-z PMC 바로가기 [Article Type] Article

COVID-19: Coagulopathy, Risk of Thrombosis, and the Rationale for Anticoagulation

Review

Published on 2020-07-172022-10-31
Journal: Clinical and applied thrombosis/hemostasis : offic [Category] COVID-19, MERS, SARS,

[키워드] Adapted addition Anticoagulant anticoagulation bleeding event can be used caused characterized coagulation parameter Coagulopathy complex COVID-19 cytokine d -dimer death decrease dosage dose effective Effects exaggerated inflammatory response Factor hematology IMPROVE incidence increase in Limited LMWH lung failure manifestation Microvascular thrombosis new coronavirus SARS-CoV-2 Novel coronavirus infection outcome parameter Patient patients patients with COVID-19 prognostic proportion rationale reduction in reported risk Sepsis severe COVID-19 manifestations severe COVID-19 patients shown Society Standard dose syndrome thrombosis
[DOI] 10.1177/1076029620938149 PMC 바로가기 [Article Type] Review

DVT incidence and risk factors in critically ill patients with COVID-19

Observational Study

Published on 2020-06-302022-10-04
Journal: Journal of Thrombosis and Thrombolysis [Category] MERS, 임상,

Randomised controlled trial comparing efficacy and safety of high versus low Low-Molecular Weight Heparin dosages in hospitalized patients with severe COVID-19 pneumonia and coagulopathy not requiring invasive mechanical ventilation (COVID-19 HD): a structured summary of a study protocol

Letter

Published on 2020-06-262022-10-29
Journal: Trials [Category] Coronavirus, SARS,

[키워드] 1:1 24 hour Administered airway allocation concealment Alpha ambient analysed aneurysms Anticoagulant treatment anticoagulation antiplatelet Arm arterial assigned Atrial fibrillation bleeding bleeding event block size Blood BMI Body Breastfeeding breath calculated Cancer clinical clinically Coagulopathy Concomitant conjunctival Continuous contributed Control control group Controlled trial corpus COVID-19 COVID19 criteria Critical D-dimer D-dimer level Day death defined detect diagnostic discharged disease severity dissemination dosage dose effective Efficacy and safety element enoxaparin Epistaxis EudraCT event events expected fibrinogen level gingival bleeding group Haemoglobin haemoptysis health-care hematemesis hematoma hemodynamic heparin High dose high risk history hospital discharge Hospital stay hospitalized patient hypersensitivity Hypothesis IL-6 Impaired impairing improvement IMV In-hospital indication initiated Inpatient INR internal Intervention intervention group Intra-articular intramuscular invasive Invasive mechanical ventilation involved Italian Italy laboratory parameter LMWH low dose low-molecular weight heparin macroscopic Major major bleeding management Mechanical mechanical ventilation medical intervention Medicine Modena NIV Non-invasive number objective occur Occurrence open label ophthalmic oral anticoagulant outcome oxygen paO2/fiO2 parallel group participant pathology Patient performed Pharyngeal swab plasma Platelet Pneumonia positive pregnancy test Presence pressure Primary outcome prophylactic dose prosthetic protocol random randomisation randomised randomised controlled randomised controlled trial randomization Rate receiving recorded recruited Rectal Bleeding reduce reduction in Registered renal function reported required respiratory risk risk of death Sample size SARS-CoV-2 secondary secure Severe COVID-19 pneumonia severe disease significantly Spontaneous standard oxygen therapy Stata status stratified stroke study drug Study protocol subcutaneously surgical susceptible symptomatic syndrome therapeutic dose therapy thrombocytopenia time transfusion Treatment unfractionated heparin unit Vascular venipuncture Venous Thromboembolism web-based system website weight Withdrawal worsening
[DOI] 10.1186/s13063-020-04475-z PMC 바로가기 [Article Type] Letter

Prevention of thrombotic risk in hospitalized patients with COVID-19 and hemostasis monitoring

Review

Published on 2020-06-192022-11-01
Journal: Critical Care [Category] COVID-19,

[키워드] acute respiratory distress added adjusted Anticoagulant Anticoagulant treatment ARDS body mass index changes characterized Coagulation coronavirus COVID-19 criteria curative D-dimer D-dimer levels defined Diagnosis dialysis dose ECMO extracorporeal membrane oxygenation fibrinogen Fibrinogen levels form Hemostasis heparin higher risk hospitalized patient hypercoagulability ICU ICU Patients increase in Infection Inflammation Inflammatory intensive care intermediate dose LMWH low molecular weight management monitoring obese patient obesity Oxygen requirement prevention Prophylaxis reflected renal risk factor Risk factors severe COVID-19 severity severity of COVID-19 Standard Standard dose syndrome the SARS-CoV-2 therapeutic dose thromboembolic risk Thromboembolism thrombosis thrombotic risk Treatment unfractionated heparin ventilated patients with COVID-19
[DOI] 10.1186/s13054-020-03000-7 PMC 바로가기 [Article Type] Review

Anticoagulation Options for Coronavirus Disease 2019 (COVID-19)-Induced Coagulopathy

Internal Medicine

Published on 2020-05-162022-10-31
Journal: Cureus [Category] COVID-19,